Hypoglycemia Induces Pro-Inflammatory Functional Changes

Share this content:
Hypoglycemia Induces Pro-Inflammatory Functional Changes
Hypoglycemia Induces Pro-Inflammatory Functional Changes

MONDAY, Jan. 30, 2017 (HealthDay News) -- Hypoglycemia can promote mobilization of specific subsets of leukocytes and induce pro-inflammatory functional changes in immune cells, according to a study published online Jan. 23 in Diabetes.

Jacqueline M. Ratter, from Radboud University Medical Center in Nijmegen, Netherlands, and colleagues examined whether the composition and inflammatory function of immune cells adapt a more pro-inflammatory state after hypoglycemia. The authors used ex vivo stimulations of peripheral blood mononuclear cells (PBMCs) and monocytes obtained during hyperinsulinemic euglycemic-hypoglycemic clamps in 11 healthy participants, 10 patients with type 1 diabetes with normal awareness of hypoglycemia (NAH), and 10 patients with impaired awareness of hypoglycemia (IAH).

The researchers found that in healthy controls and patients with NAH, but not those with IAH, hypoglycemia increased leukocyte numbers. There was a strong correlation for leukocytosis with the adrenaline response to hypoglycemia. PBMCs and monocytes displayed a more robust cytokine response to microbial stimulation after hypoglycemia versus euglycemia ex vivo; in patients with IAH the response was less pronounced. In PBMCs, hypoglycemia increased the expression of markers of demargination and inflammation.

"We conclude that hypoglycemia promotes mobilization of specific leukocyte subsets from the marginal pool and induces pro-inflammatory functional changes in immune cells," the authors write. "Inflammatory responses were less pronounced in IAH, indicating that counterregulatory hormone responses are key modulators of hypoglycemia-induced pro-inflammatory effects."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »